{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:32:30Z","timestamp":1793165550164,"version":"4.5.0"},"reference-count":11,"publisher":"The Korean Society of Nephrology","issue":"6","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gilead Sciences Inc.","id":[{"id":"https:\/\/ror.org\/056546b03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["krcp-ksn.org"],"crossmark-restriction":true},"short-container-title":["Kidney Res Clin Pract"],"published-print":{"date-parts":[[2026,10,28]]},"abstract":"<jats:p>Background: Concentration of circulating soluble tumor necrosis factor receptor 1 is associated with faster progression in patients with diabetic kidney disease based on data obtained from large longitudinal cohort studies. A cutpoint of 4.3 ng\/mL baseline plasma concentration was identified to stratify patients and predict clinical outcome. We set out to test the prognostic utility of this cutpoint in a randomized clinical trial. Methods: Soluble tumor necrosis factor receptor 1 concentration was measured across plasma samples from Joslin cohort and selonsertib trial cohort. Estimated glomerular filtration rate slope was calculated using a patient-specific linear regression model based on serum creatinine concentration and compared between the cohorts. Kidney-related events were plotted using Kaplan\u2013Meier estimates for both cohorts. Results: Participants from both the clinical study cohort and the observational cohort showed an inverse relationship between baseline plasma concentrations of tumor necrosis factor receptor 1 and estimated glomerular filtration rate. When stratified based on baseline soluble tumor necrosis factor receptor 1 cutpoint, higher probability of experiencing a clinical event was found in patients with levels of soluble tumor necrosis factor receptor 1 exceeding 4.3 ng\/mL in either of the cohorts. Conclusion: We demonstrated the prognostic utility of plasma concentrations of circulating soluble tumor necrosis factor receptor 1 in identifying individuals with diabetic kidney disease at an elevated risk of progressive kidney function decline in a randomized clinical study setting. This data supports previous findings from large observational cohorts and supports the use of this marker as a reliable predictor of disease outcome.<\/jats:p>","DOI":"10.23876\/j.krcp.25.198","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:27:12Z","timestamp":1785824832000},"page":"933-939","update-policy":"https:\/\/doi.org\/10.23876\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic stratification in a diabetic kidney disease trial using plasma concentrations of soluble tumor necrosis factor receptor 1"],"prefix":"10.23876","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5444-0222","authenticated-orcid":true,"given":"Vladimir","family":"Petrovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-6184","authenticated-orcid":true,"given":"Vladislav A.","family":"Malkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7752-0934","authenticated-orcid":true,"given":"Andrew N.","family":"Billin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6905-6649","authenticated-orcid":true,"given":"Uptal D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-894X","authenticated-orcid":true,"given":"Pablo E.","family":"Pergola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7599-0534","authenticated-orcid":true,"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9295-6031","authenticated-orcid":true,"given":"Jan","family":"Skupien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1705-2953","authenticated-orcid":true,"given":"Andrzej S.","family":"Krolewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"9960","reference":[{"key":"ref1","first-page":"49","volume-title":"Diabetic kidney disease: world wide difference of prevalence and risk factors","author":"Gheith","year":"2016"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.046"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0415-5"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.010"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2018121231"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1172\/jci99768"},{"key":"ref7","volume-title":"Soluble tumor necrosis factor receptor 1 (sTNFR1) is prognostic for end-stage kidney disease over 48 weeks in a randomized clinical trial in moderate to advanced diabetic kidney disease","author":"Tarrant","year":"2019"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2019010007"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5296.90"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13705"},{"key":"ref11","volume-title":"Selonsertib reduces tumor necrosis factor alpha\u2013induced markers of injury and inflammation in an organ-on-a-chip model of proximal tubular injury","author":"Badal","year":"2020"}],"container-title":["Kidney Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/krcp-ksn.org\/upload\/pdf\/j-krcp-25-198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/krcp-ksn.org\/journal\/view.php?doi=10.23876\/j.krcp.25.198","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/krcp-ksn.org\/upload\/pdf\/j-krcp-25-198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:43:47Z","timestamp":1793162627000},"score":1,"resource":{"primary":{"URL":"http:\/\/krcp-ksn.org\/journal\/view.php?doi=10.23876\/j.krcp.25.198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,28]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"URL":"https:\/\/doi.org\/10.23876\/j.krcp.25.198","relation":{},"ISSN":["2211-9140"],"issn-type":[{"value":"2211-9140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,28]]},"assertion":[{"value":"2025-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-28","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}